恆發光學(01134.HK)附屬簽訂電動車合作項目諒解備忘錄
恆發光學(01134.HK)公佈,直接全資附屬東宇科技與比依威新能源訂立諒解備忘錄,雙方擬就換電及氫電動汽車項目進行合作。東宇科技及比依威新能源將按60:40的比例向該項目注資,及分享該項目產生的回報。東宇科技的注資將以現金支付,比依威新能源將以提供知識產權及技術知識的方式作出其注資。
東宇科技主要負責提供該項目的初始資金。比依威新能源主要負責按照諒解備忘錄就該項目提供技術知識及知識產權、相關程序事宜、日常營運以及營銷及銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.